Updated:
Yonjin Venture
Yonjin Venture is the North America and Europe investment arm of Yongjin Group, based in Shanghai with headquarters in China. It focuses on early- and...
Yonjin Venture
Yonjin Venture is the North America and Europe investment arm of Yongjin Group, based in Shanghai with headquarters in China. It focuses on early- and mid-stage life science companies in therapeutics, diagnostics, and medical devices. Yonjin Venture has made 18 investments, including a Series A - V investment in Rapafusyn Pharmaceuticals on September 04, 2025.
General information
Firm type
Venture Capital
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
Cambridge, MA, United States
Frequently asked questions
Who runs investment decisions at Yonjin Venture?
No named principals or investment committee members appear in public records, regulatory filings, or press coverage. The firm does not maintain a public LinkedIn page or list team members on its website. This absence of disclosed leadership makes it difficult for external allocators to assess the decision-making structure or track record of the individuals deploying capital.
Is Yonjin Venture structured as a venture capital fund or a family office?
The firm self-identifies as a private equity asset manager focused on early-stage venture, which suggests a fund structure. However, no SEC Form ADV registration, Form D filings, or public fund announcements confirm this classification. The lack of visible limited partners or fund closes leaves open the possibility that Yonjin operates as a personal investment vehicle rather than a pooled fund.
Does Yonjin Venture participate in fund commitments or only direct deals?
Without disclosed portfolio data, it is not possible to determine whether Yonjin makes direct investments into startups, participates as a limited partner in other venture funds, or engages in both. The firm's stated strategy covers seed and startup stages, which typically implies direct equity investments, but no deal announcements or portfolio company rosters are publicly available to confirm this.
What sectors does Yonjin Venture target?
No sector focus is publicly disclosed. The firm's Cambridge location suggests potential exposure to life sciences, deep tech, and university spinouts given the concentration of MIT and Harvard-linked startups in the area, but no confirmed investments or stated thesis support this inference.
How can an institutional allocator conduct due diligence on Yonjin Venture?
Allocators face significant hurdles given the absence of public portfolio data, team biographies, fund performance, or regulatory filings. Direct outreach to the firm via its website remains the only visible path to initiate diligence. Without audited financials, track record documentation, or referenceable co-investors, the firm falls below standard institutional due-diligence thresholds as of the current public record.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: